BioSight
Companies
KAMADA LTD logo

KMDA

NASDAQREHOVOT, L3
KAMADA LTD

KAMADA LTD develops and distributes plasma-derived products and biosimilars, operating across therapeutic areas including specialty pharmaceuticals and biopharmaceuticals. The company pursues growth through four pillars: expanding its commercial portfolio of products, distributing third-party pharmaceuticals in Israel and the Middle East and North Africa region, operating plasma collection facilities, and pursuing merger and acquisition opportunities. KAMADA is a commercial-stage company with existing revenue streams and projects revenues of $200–205 million by fiscal 2026.

Price history not yet available for KMDA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar